Akili alphabet

Author: c | 2025-04-24

Akilis Alphabet Akili and Me for Android, free and safe download. Akilis Alphabet Akili and Me latest version: Fun matching letters game for toddlers. Akilis Alphabet Akili and Me for Android, free and safe download. Akilis Alphabet Akili and Me latest version: Fun matching letters game for toddlers.

Alphabet Songs with Akili - Album by Akili and Me

About Akili's Alphabet Akili's Alphabet is an app developedby Ubongo. The app has been available since March 2019. It's currently not in the top ranks. It's rated 4.30 out of 5 stars, based on 47 ratings. The last update of the app was on March 3, 2019. Akili's Alphabet has a content rating "Everyone". Akili's Alphabet has an download size of 85.51 MB and the latest version available is 1.2. Akili's Alphabet costs $0.99 to download. Description Akili’s Alphabet gives your 3 to 6-year-old a head start in developing their literacy skills! With the help of Akili and her friends, your toddler will discover that learning can be fun, and build an enthusiasm for developing their pre-literacy skills that will help them succeed in the first grade!WHY CHOOSE AKILI'S ALPHABET?- QUALITY: Created in Africa by a skilled team of education experts, app developers, graphics designers, animators and sound engineers- ASSURED: Designed with kids in mind and based on research into how preschoolers learn best- REPRESENTATION: Akili is a curious and smart four-year-old who wants to learn... the perfect role model for all children- TRIED AND TESTED: Thousands of children have used the app and they love it (so do their parents)!HOW IT WORKSFrom the rainbow home screen you can choose a letter to learn. Then find and drag the matching letter into the letter’s shape. Whenever you touch a letter it will make a sound, this will help your child learn to also identify letters by their unique sounds. Once you get it right, you’ll be rewarded with pictures of items that start with that letter and a song to help you remember the letter and new words!LEARNING BENEFITS- Identify letter sounds- Match letter shapes- Learn new words through songs- Play independently- Learn at his/her own pace- Have fun learningThese all help to develop your child's pre-literacy skills, meaning they will be ready to excel when they enter the classroom!KEY FEATURES- Learn over 80 new words- Play in a safe, secure space- MADE for 3, 4, 5 and 6 year olds- NO high scores, so no failure or stress- Works OFFLINE, without an internet connectionTHE TV SHOWAkili and Me is an edutainment cartoon from Ubongo, creators of Ubongo Kids and Akili and Me - great learning programs made in Africa, for Africa.Akili is a curious 4-year-old who lives with her family at the foot of Mt. Kilimanjaro, in Tanzania. She Has a secret: every night when she falls asleep, she enters the magical world of Lala Land, where she and her animal friends learn all about language, letters, numbers and art, while developing kindness and coming to grips with their emotions and rapidly changing toddler lives! With broadcast in 5 countries and a massive international online following, kids from around the world love going on magical learning adventures with Akili!Watch videos of Akili and Me on YouTube, and check the website www.ubongo.org to see if the show airs in your country. ABOUT UBONGOUbongo is a social enterprise that creates interactive edutainment for kids in Africa, using the technologies they already have. We entertain kids to LEARN & LOVE LEARNING!We leverage the power of entertainment, the reach of mass media, and the connectivity provided by mobile devices to deliver high-quality, localized edutainment and educational content to African kids, giving them the resources and motivation to learn independently – at their own pace. All proceeds from app sales will go towards creating more FREE educational content for children in Africa. TALK TO USIf you have questions, comments, advice or need help and support with this app please talk to us at: [email protected]. We’re always happy to hear from you.">Show more More data about Akili's Alphabet Price $0.99 Rating 4.30 based on 47 ratings Ranking Not ranked Version 1.2 App download size 85.5 MB Suitable for Everyone Alternatives for the Akili's Alphabet app More from Ubongo Changelog No changelog data Developer information for Ubongo Share Comments on Akili's Alphabet for iOS We don't have enough comments to show example comments. Please check back later. App Store Rankings This app is not ranked Technologies used by Akili's Alphabet Back to top

'Akili Alphabet' Throw Blanket – Akili and Me

Including younger children (3 to 7 years old), teens, and adults, while simultaneously working with a partner to gain approval as a treatment for pediatric ADHD in Japan.Strong clinical rigor. Akili has completed 20 clinical trials across 2,900 patients and nine disease populations. In addition, Akili’s clinical studies and data have been published in 16 leading peer-reviewed journals.Robust research and clinical pipeline. Akili has a strong development pipeline, initially focused on treatments for cognitive impairments across nine patient populations. In addition, Akili is progressing early discovery for two new platform technologies to address additional cognitive impairments and facilitate broader reach across disease spectrums. Akili is poised to begin pivotal studies in multiple indications where proof-of-concept has been achieved, including additional ADHD populations, ASD, MS, and MDD.Management CommentsEddie Martucci, Chief Executive Officer of Akili, said: “This transaction represents the next step in our journey to become the world’s leading digital medicine company directly targeting neurological function. Over the past 10 years, we have created a platform representing a new era of cognitive medicine, driven by our fundamental focus on patients, advanced science and proprietary technology, and the mission-driven hard work of our entire team. We believe medicine now can be both effective and engaging. Social Capital Suvretta shares our vision for the future, and we look forward to applying our combined experience as we drive the commercialization of our platform and advance our deep pipeline of prescription digital therapeutics to help people living with cognitive impairments across the globe.”Chamath Palihapitiya, Founder and CEO of Social Capital and Chairman and CEO of SCS, commented: “Akili is taking a new approach to cognitive science – using software to target our underlying cognitive function and creating an entirely new class of medicine as a byproduct. With its first-ever, clinically validated digital therapeutic (EndeavorRx®), Akili has the unique opportunity to change how we treat pediatric ADHD. They have also laid the groundwork to treat a wide range of other cognitive issues affecting tens of millions of people around the world.”Kishen Mehta, Portfolio Manager of the Averill strategy at Suvretta Capital Management and President of SCS, said: “Akili has created a unique disease-agnostic technology platform with an advanced pipeline of product candidates across multiple indications where proof-of-concept has already been achieved. The Company is leading the advancement of digital cognitive therapies with an FDA-cleared product already on the market, and we believe Akili has only just. Akilis Alphabet Akili and Me for Android, free and safe download. Akilis Alphabet Akili and Me latest version: Fun matching letters game for toddlers. Akilis Alphabet Akili and Me for Android, free and safe download. Akilis Alphabet Akili and Me latest version: Fun matching letters game for toddlers.

Akili's Alphabet Kid's Leggings – Akili and Me

Valuation in determining whether or not to pursue the proposed transaction, (v) the inability to complete the PIPE Investment, (vi) the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement, (vii) the effect of the announcement or pendency of the transaction on Akili’s business relationships, operating results, and business generally, (viii) risks that the proposed transaction disrupts current plans and operations of Akili or diverts management’s attention from Akili’s ongoing business operations and potential difficulties in Akili employee retention as a result of the announcement and consummation of the proposed transaction, (ix) the outcome of any legal proceedings that may be instituted against Akili or against SCS related to the Merger Agreement or the proposed transaction, (x) the ability to maintain the listing of SCS’s securities on a national securities exchange, (xi) the price of SCS’s securities may be volatile due to a variety of factors, including changes in the competitive and highly regulated industries in which SCS plans to operate or Akili operates, variations in operating performance across competitors, changes in laws and regulations affecting SCS’s or Akili’s business, and changes in the combined capital structure, (xii) the ability to implement business plans, forecasts, and other expectations after the completion of the proposed transaction, and identify and realize additional opportunities, (xiii) the ability of Akili to successfully commercialize EndeavorRx® and continue to advance its clinical development pipeline, (xiv) the ability to recognize the anticipated benefits of the proposed transaction, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees, (xv) the evolution of the markets in which Akili competes, (xvi) the ability of Akili to defend its intellectual property and satisfy regulatory requirements, (xvii) the costs related to the proposed transaction, (xviii) the impact of the COVID-19 pandemic on Akili’s business, (xix) Akili’s expectations regarding its market opportunities and (xx) the risk of downturns and a changing regulatory landscape in the highly competitive industry in which Akili operates. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of SCS’s registration on Form S-1 (File Nos. 333-256723 and 333-257543), SCS’s quarterly report on Form 10-Q for the quarter Scratched the surface of this new and exciting field of medicine. We look forward to working with Akili to accelerate the Company’s growth and allow it to continue developing treatment options for the hundreds of millions of people living with cognitive impairments.”Transaction OverviewThe transaction implies a post-money equity value of the combined company of up to approximately $1 billion and is expected to deliver up to $412 million in gross cash proceeds to the Company, including the contribution of up to $250 million of cash held in SCS’s trust account and $162 million from PIPE investors at $10 per share. All references to available cash from the trust account and retained transaction proceeds are subject to any redemptions by the public shareholders of SCS and payment of transaction expenses. Akili plans to use the net proceeds to help fund the Company’s go-to-market strategy, to further advance its pipeline of prescription digital therapeutics targeting a range of chronic and acute cognitive disorders, and for other general corporate purposes.Existing Akili shareholders will roll 100% of their equity into the combined company and will be eligible to receive additional SCS shares pursuant to an earnout based on the combined company’s future stock performance. Chamath Palihapitiya is expected to join Akili’s board of directors as chair, upon the close of the transaction.The proposed business combination, which has been unanimously approved by the boards of directors of both Akili and SCS, is expected to close in mid-2022, subject to approval by SCS’s and Akili’s shareholders, regulatory approvals, and other customary closing conditions.AdvisorsMorgan Stanley & Co. LLC (“Morgan Stanley”) and Cowen and Company, LLC (“Cowen”) are serving as financial advisors to Akili. Morgan Stanley, Credit Suisse, and Cowen are serving as co-placement agents to SCS with respect to the portion of the PIPE financing raised from non-insider qualified institutional buyers and institutional accredited investors. Morgan Stanley, Credit Suisse, and Cowen are not acting as agents or participating in any role with respect to, and will not earn any fees from, the portion of the PIPE financing raised from insiders and individual investors. Credit Suisse and Cowen are serving as capital markets advisors to Akili. BofA Securities, Inc. is acting as capital markets advisor to SCS.Goodwin Procter LLP is serving as legal counsel to Akili. Wachtell, Lipton, Rosen & Katz is serving as legal counsel to SCS. Skadden, Arps, Slate, Meagher & Flom LLP is serving as

Alphabet Songs with Akili by Akili and Me on Apple Music

Akili’s leading digital therapeutic platform combines science and technology to address cognitive impairments in patients, reimagining how central nervous system medicines are designed, developed, and deliveredTransaction will support commercial launch of EndeavorRx®, a first-of-its-kind, FDA-cleared and CE-marked prescription digital therapeutic for pediatric ADHD, as well as advance clinical development pipeline across multiple neuropsychiatric diseases, including expanded ADHD populations, multiple sclerosis, autism, and depressionTransaction values the combined company at an equity value post-money of up to approximately $1 billion and is expected to provide up to $412 million in gross cash proceedsFully committed PIPE of $162 million led by $100 million from Social Capital with remaining $62 million from new and existing investors including: Suvretta Capital Management’s Averill strategy, Apeiron Investment Group, Temasek, co-founder PureTech Health, Polaris Partners, Evidity Health Capital, JAZZ Venture Partners and Omidyar Technology VenturesChamath Palihapitiya expected to become Chair of Akili’s Board of Directors upon transaction closeBOSTON, Mass. and PALO ALTO, Calif. – January 26, 2022 – Akili Interactive (“Akili” or the “Company”), a leading digital medicine company developing cognitive treatments through game-changing technologies, has entered into a definitive agreement to become publicly traded via a merger with Social Capital Suvretta Holdings Corp. I (“SCS”) (Nasdaq: DNAA), a special purpose acquisition company. The transaction is expected to close in mid-2022, after which Akili will be listed on the Nasdaq stock market under the new ticker symbol “AKLI.” As a public company with world-class backing and strong financial flexibility, Akili will be positioned to pioneer a new class of digital medicines for millions of people living with cognitive impairment. New Digital Approach to Cognitive MedicineThe Akili software platform was built on the belief that directly engaging brain function is the next frontier of science and medicine. Cognitive impairments – including poor concentration, memory loss, difficulties learning new skills, and difficulties with decision making – are in aggregate among the largest unmet medical needs, and are increasingly recognized as contributing to or associated with dozens of chronic diseases and acute illnesses, including attention-deficit/hyperactivity disorder (ADHD), major depressive disorder (MDD), multiple sclerosis (MS), and autism spectrum disorder (ASD), as well as postoperative cognitive dysfunction and COVID-19 “brain fog.”Despite the rapidly growing prevalence of these conditions, the acute exacerbation of these issues by the pandemic’s impact, and the chronic, escalating cognitive overload from the proliferation of on-demand attention-capturing technology, there has been limited innovation of novel treatment options. Specifically, current treatment

Herufi na Akili (Akili’s Alphabet in Kiswahili) is launched!

Options are designed to focus on symptoms and coping strategies instead of directly targeting cognitive functioning. These therapeutic shortfalls are especially concerning for younger populations who are potentially facing a lifetime of managing these conditions.Akili’s First-of-Its-Kind, Clinically Validated TherapeuticBy harnessing advances in cognitive neuroscience and consumer technology, Akili is changing the neuropsychiatric treatment paradigm. Akili’s patented and clinically validated technology platform represents a new category of software-based medicine: advanced and proprietary digital therapeutics that are designed to directly target neural physiology to better serve the needs of patients and their families.Akili’s core therapeutic engine, the Selective Stimulus Management Engine (SSME™), is specifically designed to target and activate neural systems involved in attentional control. This core platform has the potential to be applied across a diverse set of indications within psychiatry and neurology. Backed by robust clinical research, Akili’s treatments are delivered to patients through engaging interactive mobile games, personalized to each individual and built to feel like high-end entertainment products.The SSME™ technology has already demonstrated proof-of-concept in controlled trials targeting attention and cognitive dysfunction in ADHD, ASD, MS, and MDD. Built on the SSME™ technology, Akili developed EndeavorRx®, the first-ever FDA-cleared prescription video game and the first-ever FDA-cleared commercial product indicated to improve attention function in children between the ages of 8 to 12 years with primarily inattentive or combined-type ADHD (see full indication below). Key Investment Highlights:Patented and clinically validated technology platform. Developed with the collaboration of cognitive neuroscientists and mobile game developers, Akili’s proprietary technology is designed to target key neural systems underlying specific cognitive functions through adaptable, personalized closed-loop algorithms. The technology is clinically validated, using recognized endpoints, and delivered through smartphones or other mobile devices.First-and-only FDA-cleared video game-based digital therapeutic. Anticipated to launch in the second half of 2022, EndeavorRx® is the first and only prescription video game treatment with FDA clearance and a CE mark (designating it has met European health, safety, performance, and environmental requirements) in pediatric ADHD. EndeavorRx® has been validated through multiple clinical trials, including large randomized, controlled trials demonstrating improved patient outcomes.Large and growing market opportunity. Tens of millions of people worldwide live with cognitive health issues, and many are actively searching for better solutions. With EndeavorRx®, Akili is initially targeting the approximately $10 billion U.S. ADHD market. EndeavorRx® will first launch for the FDA-cleared 8 to 12-year-old pediatric population. Akili is also seeking to expand into other U.S. ADHD populations,. Akilis Alphabet Akili and Me for Android, free and safe download. Akilis Alphabet Akili and Me latest version: Fun matching letters game for toddlers. Akilis Alphabet Akili and Me for Android, free and safe download. Akilis Alphabet Akili and Me latest version: Fun matching letters game for toddlers.

Akili's Alphabet Flash Cards (English) – Akili and Me

Shareholders in connection with the proposed transaction. A list of the names of such directors and executive officers and information regarding their interests in the proposed transaction between Akili and SCS will be contained in the proxy statement/prospectus when available. You may obtain free copies of these documents as described in the preceding paragraph.No Offer or SolicitationThis communication shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transaction. This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act or an exemption therefrom. This press release may be deemed to be solicitation material in respect of the proposed transactions contemplated by the proposed business combination between Akili and SCS.Forward-Looking StatementsThis communication may contain certain forward-looking statements within the meaning of the federal securities laws with respect to the proposed transaction between Akili and SCS. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this communication, including but not limited to: (i) the risk that the proposed transaction may not be completed in a timely manner or at all, which may adversely affect the price of SCS’s securities, (ii) the risk that the proposed transaction may not be completed by SCS’s business combination deadline and the potential failure to obtain an extension of the business combination deadline if sought by SCS, (iii) the failure to satisfy the conditions to the consummation of the proposed transaction, including the adoption of the Merger Agreement by the shareholders of SCS and the satisfaction of the minimum cash condition, (iv) the lack of a third party